Business Daily from THE HINDU group of publications
Thursday, May 22, 2008
ePaper | Mobile/PDA Version | Audio
Business Daily from THE HINDU group of publications Thursday, May 22, 2008 ePaper | Mobile/PDA Version | Audio |
|
|
|
|
|
|
|
Corporate
-
Overseas Investments
Our Bureau New Delhi, May 21 Pharma-major Ranbaxy Laboratories Ltd on Wednesday said it has commenced its operations in Yemen, strengthening its presence in the West Asian region. Ranbaxy has tied up with Pharma Ltd (Natco) as business partners for its Yemen operations. Ranbaxy will focus on therapy areas such as anti-infectives, gastro-intestinal, cholesterol lowering and anti-allergic categories in Yemen. Commenting on the launch, Mr Sanjeev I. Dani, Senior Vice-President & Regional Director — Asia & CIS, Ranbaxy, said, “Yemen is an important market for us. Our endeavour is to bring down the health care cost in Yemen by providing value-added international quality products at affordable prices.” With this the company will have presence in 11 countries in the West Asian region where it has a strong product pipeline with 160 approvals. “UAE is the single largest market for the region where Ranbaxy enjoys the distinction of being the largest generic company with 20 products. Two of them feature among the top 50 pharmaceutical products in UAE. Ranbaxy is ranked 12th and also the fastest growing amongst the Top 15 pharmaceutical companies in UAE including the originators. In Oman, Ranbaxy is the No.1 company in the private sector for the past three years,” said a press release. More Stories on : Overseas Investments | Pharmaceuticals | Ranbaxy Laboratories Ltd
Article E-Mail :: Comment :: Syndication :: Printer Friendly Page
|
Stories in this Section |
 |
|
The Hindu Group: Home | About Us | Copyright | Archives | Contacts | Subscription Group Sites: The Hindu | The Hindu ePaper | Business Line | Business Line ePaper | Sportstar | Frontline | The Hindu eBooks | The Hindu Images | Home |
Copyright © 2008, The
Hindu Business Line. Republication or redissemination of the contents of
this screen are expressly prohibited without the written consent of
The Hindu Business Line
|